Insilico: linking target discovery and generative chemistry AI platforms for a drug discovery breakthrough

Deep learning in biopharma has come of age. After working for years to understand how to apply an artificial intelligence (AI) approach to biotechnology, Insilico Medicine recently disclosed the discovery of a novel drug target and novel molecule using AI. The discovery, a world first, took less than 18 months and cost 10% as much as a conventional program. Having validated its platforms, Insilico is now making the technology available to big pharmaceutical companies. Insilico was founded in 2014 by a team of long-term academic collaborators, Alex Zhavoronkov and Alex Aliper.